Evidence map›Paper›PMID 37896144›Full record

ArticlePharmaceutics2023

Folate-Targeted Nanoliposomal Chemophototherapy.

Upendra Chitgupi, Yiru Qin, Sanjana Ghosh, Breandan Quinn, Kevin Carter, Xuedan He, Ulas Sunar, Jonathan F Lovell

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Special Issue "Application Progress of Liposomes in Drug Development".International journal of molecular sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Upendra ChitgupiDepartment of Biomedical Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA.ORCID 0000-0002-6548-7847
Yiru QinDepartment of Biomedical Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA.
Sanjana GhoshDepartment of Biomedical Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA.
Breandan QuinnDepartment of Biomedical Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA.
Kevin CarterDepartment of Biomedical Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA.
Xuedan HeDepartment of Biomedical Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA.
Ulas SunarDepartment of Biomedical Engineering, Stony Brook University, Stony Brook, NY 11794, USA.ORCID 0000-0002-0623-7522
Jonathan F LovellDepartment of Biomedical Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA.ORCID 0000-0002-9052-884X
University at Buffalo, State University of New York · USStony Brook University · US

Funding

Light-Triggered Drug Release in Primed Pancreatic TumorsR01EB017270 · NIBIB · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI LOVELL, JONATHAN F · 2013 to 2021
$3.5M
Targeting Tumors with Resealable Nanovesicles Permeabilized by NIR LightDP5OD017898 · OD · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI LOVELL, JONATHAN F · 2013 to 2017
$1.9M
Quantitative Fluorescence Imaging-Guided Detection and Targeted Therapy Monitoring Platform for Ovarian Cancer MicrometastasesR01CA243164 · NCI · WRIGHT STATE UNIVERSITY · PI Ulas Sunar · 2020 to 2026
$1.7M
NCI NIH HHS R01 CA243164NIBIB NIH HHS R01 EB017270NIH HHS DP5 OD017898
6 · The paper itself

Abstract

Light-responsive liposomes have been developed for the on-demand release of drugs. However, efficient delivery of chemotherapeutic drugs to tumor for cancer theranostics remains a challenge. Herein, folic acid (FA), an established ligand for targeted drug delivery, was used to decorate light-sensitive porphyrin-phospholipid (PoP) liposomes, which were assessed for FA-targeted chemophototherapy (CPT). PoP liposomes and FA-conjugated PoP liposomes were loaded with Doxorubicin (Dox), and physical properties were characterized. In vitro, FA-PoP liposomes that were incubated with FA receptor-overexpressing human KB cancer cells showed increased uptake compared to non-targeted PoP liposomes. Dox and PoP contributed towards chemophototherapy (CPT) in vitro, and PoP and FA-PoP liposomes induced cell killing. In vivo, mice bearing subcutaneous KB tumors treated with PoP or FA-PoP liposomes loaded with Dox, followed by 665 nm laser treatment, had delayed tumor growth and improved survival. Dox delivery to tumors increased following laser irradiation for both PoP and FA-PoP liposomes. Thus, while Dox-FA-PoP liposomes were effective following systemic administration and local light irradiation in this tumor model, the FA targeting moiety did not appear essential for anti-tumor responses.

Indexed as

chemophototherapydoxorubicinfolatefolic acidliposomephotodynamic therapy

Identifiers

PMID37896144
PMCPMC10609802
OpenAlexW4387057101

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.